| Document |
Document Title |
|
WO/2024/083099A1 |
Disclosed in the present invention are a drug intermediate and a preparation method therefor, and specifically disclosed are a compound as represented by formula (I) and a preparation method therefor.
|
|
WO/2024/083160A1 |
Provided are a crystal form and an amorphous substance of an indoline spiro compound represented by formula (1), and a preparation method therefor and the use thereof. The X-ray powder diffraction pattern of the crystal form comprises ch...
|
|
WO/2024/086777A2 |
Compositions and methods are provided for inhibiting the replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
|
|
WO/2024/084406A1 |
The invention relates to a process for synthesising acyl derivatives of glutathione and cysteine which involves considerable environmental advantages, because said compounds can be synthesised effectively without the use of environmental...
|
|
WO/2024/083164A1 |
Provided are an anisole solvate of an indoline spiro compound represented by formula (1), and a crystal form thereof, a preparation method therefor and the use thereof. The X-ray powder diffraction pattern of the crystal form comprises c...
|
|
WO/2024/044098A3 |
This disclosure provides peptide based compounds, compositions, and methods to treat medical disordeds, such as complement-mediated disorders, including complement C1s-mediated disorders, such as acute antibody-mediated rejection, amyotr...
|
|
WO/2024/078485A1 |
The present invention belongs to the technical field of tumor immunotherapy, and specifically relates to a signal receptor used for targeting a tumor microenvironment and a cell for targeted treatment of tumors. The signal receptor compr...
|
|
WO/2024/080398A1 |
The present invention relates to a peptide having activities to promote hair growth or to prevent or inhibit alopecia. The peptide of the present invention promotes the proliferation of hair follicle dermal papilla cells (HFDPC) and huma...
|
|
WO/2024/078618A1 |
Disclosed in the present invention are a crystal form of a cyano-substituted polypeptide compound and a preparation method therefor. Specifically disclosed are a crystal form of the compound of formula (I) and a preparation method therefor.
|
|
WO/2024/079067A1 |
The invention provides viral protease inhibitors having the general formula (I) wherein the variables are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compou...
|
|
WO/2024/078294A1 |
An amorphous form of a ketoamide derivative and a preparation method therefor.The amorphous form has good stability, thus has a certain medicinal prospect, and provides a feasible active pharmaceutical ingredient for subsequent drug deve...
|
|
WO/2024/075813A1 |
Provided are: a novel diketopiperazine compound for rapid and easy synthesis of various polypeptides; and a method for manufacturing the same. The diketopiperazine compound is represented by general formula (1). (In the formula, R1, R2, ...
|
|
WO/2024/074651A1 |
This application relates to novel compounds and their use as SARS-CoV-2 Main Protease (Mpro) inhibitors. Compounds described herein may be useful in the treatment of SARS-CoV-2 and related viruses and disorders associated with SARS-CoV-2...
|
|
WO/2024/077006A1 |
Described herein are radiotherapeutics that target tumor cells expressing the follicle-stimulating hormone receptor (FSHR) and their use in the treatment and/or diagnosis of cancer.
|
|
WO/2024/075124A1 |
Compositions that comprise a solvent (e.g., an aqueous solvent) and a plurality of aromatic peptides that are soluble in the solvent, and non-crystalline materials formed thereof, which can be glassy and/or adhesive materials, are provid...
|
|
WO/2024/077149A2 |
Provided are crystalline forms of peptide fragments, method of preparation thereof, and use thereof for preparing peptides. The present crystalline compounds may be employed as intermediates with improved purity and physical properties f...
|
|
WO/2024/072241A1 |
The invention relates to a novel chemical compound - a diagnostic marker for use in medicine, more specifically in cancer diagnosis, in particular the diagnosis of ovarian cancer. The invention also relates to an in vitro method for dete...
|
|
WO/2024/065056A1 |
Antibody-drug conjugates (ADCs) comprising an antibody construct that specifically binds c-Met conjugated to one or more drugs, such as the auristatin analogue, compound (1), via a linker. Also described are anti-cMet antibody constructs...
|
|
WO/2024/065882A1 |
An amino acid-based multifunctional water-based liquid, a preparation method therefor and a use thereof. In the water-based liquid, water is used as a solvent, and viscous droplets rich in amino acids, oligopeptides or/and amino acid/oli...
|
|
WO/2024/069524A1 |
Novel PEG modified cyclic dipeptide compounds are disclosed. The modified cyclic dipeptide compounds contain a cyclic dipeptide and a biocompatible polymer attached to the cyclic dipeptide. The cyclic dipeptide may be proline-containing,...
|
|
WO/2024/067754A1 |
The present invention relates to the technical field of medicines, and relates to an auristatin drug with a high-stability hydrophilic linking unit and a conjugate thereof. Particularly, the present invention relates to a ligand-drug con...
|
|
WO/2024/061483A1 |
The present invention relates to a tetrapeptide binding to Cholecystokinin 2 receptor (CCK-2R), wherein the tetrapeptide is represented by formula (I) Xaa1-Xaa2-Xaa3-Xaa4 (formula (I)) or salt thereof, wherein Xaa1 is Trp, (β-(3-benzoth...
|
|
WO/2024/056779A1 |
The invention relates to crystalline form of (3S,7S,10R,13R)-13-benzyl-20-fluoro-7-isobutyl-N-(2-(3-metho
xy-1,2,4- oxadiazol-5-yl)ethyl)-6,9-dimethyl-1,5,8,11-tetraoxo-10-(2,2
,2-trifluoroethyl)-1,2,3,4,5,6,7,8,9,10,11,12,13,14- tetrade...
|
|
WO/2024/058198A1 |
Provided is a production method which is for induced pluripotent stem cells and by which induced pluripotent stem cells having high undifferentiation properties and differentiation potency are easily obtained. A production method for i...
|
|
WO/2024/059263A1 |
The invention provides novel improved methods for preparing maytansinoid derivatives with self-immolative peptide linkers as well as their synthetic precursors.
|
|
WO/2024/059119A2 |
This invention provides compounds of formula (II) or tautomers, stereoisomers, hydrates, solvates, salts, or polymorphs thereof, wherein Z1a, X1a, Ar1, X2a, W1a, Y1a, R1a, R2a, R3a, and R4a have the same meaning as that defined in the de...
|
|
WO/2024/059754A1 |
The invention is directed to polythiolated linker compounds comprising dithiolane moieties for attaching labeled biomolecules, such as polynucleotides, to metallic particles for analysis with nanopore techniques. Further disclosed a meth...
|
|
WO/2024/052922A1 |
An isolated antibody that binds to a cyclized peptide having an amino acid sequence as set forth in SEQ ID NO: 9 with an EC50 of less than 500 nM, as determined by ELISA is disclosed. Uses of same are also disclosed as well as methods of...
|
|
WO/2024/054617A1 |
The present disclosure provides delivery vehicle compositions comprising hydroxyalkyl-capped cationic peptoids, such as 2-aminopropane-1,3-diol-capped cationic peptoids, and complexes of the delivery vehicles with polyanionic compounds, ...
|
|
WO/2024/040322A1 |
The present invention involves biomimetic peptides derived from the multifunctional factor thymosin-B4 (TB4) functionalized with serotonin (5-HT- or 5-hydroxytryptamine) and/or its biological precursor 5-hydroxytryptophan (5-HTP*). More ...
|
|
WO/2024/044748A2 |
Provided according to some embodiments is a compound of Formula I, or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions comprising the same and methods of use for treating cancer and inhibiting PRX3 are also provided.
|
|
WO/2024/041535A1 |
The present disclosure relates to a nano-composition, a preparation method therefor, and use thereof. The nano-composition is formed by self-assembly of an oligopeptide containing a tryptophan dipeptide motif and cisplatin. The general f...
|
|
WO/2024/044549A1 |
Described herein are immunoconjugates comprising an: a) antigen binding region; b) an immunoglobulin heavy chain constant region; and c) a radioisotope chelating agent; wherein the molecular weight of said immunoconjugate is between 60 a...
|
|
WO/2024/044751A2 |
Provided according to some embodiments is a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions comprising the same and methods of use for treating cancer and inhibiting PRX3 are also provi...
|
|
WO/2024/041532A1 |
The present disclosure relates to a complex comprising a tetravalent platinum moiety and an oligopeptide as an axial ligand chemically linked to the platinum.
|
|
WO/2024/043523A1 |
The present invention relates to a compound specifically targeting synovium, and uses thereof. The compound prepared according to the present invention exhibits no toxicity in vitro and in vivo, is stable in biological environments, can ...
|
|
WO/2024/044744A2 |
Provided according to some embodiments is a compound of Formula (I), or a pharmaceutically acceptable salt or prodrug thereof. Pharmaceutical compositions comprising the same and methods of use for treating cancer and inhibiting PRX3 are...
|
|
WO/2024/044098A2 |
This disclosure provides compounds, compositions, and methods to treat medical disorders, such as complement-mediated disorders, including complement C1s-mediated disorders.
|
|
WO/2024/038888A1 |
The present invention addresses the problem of providing technology for heightening a small intestinal absorption property of a peptide having physiological functionality. This problem is solved via a composition containing a peptide com...
|
|
WO/2024/037520A1 |
Disclosed in the present invention are a new compound as represented by general formula I, a pharmaceutically acceptable salt, an enantiomer, a diastereoisomer and a racemate thereof, and a pharmaceutical composition containing the compo...
|
|
WO/2024/038345A1 |
The invention relates to a compound of formula (I) R1- Wm-Xn-AA1-AA2-AA3-AA4-Yo-Zp-R2, a stereoisomer and/or cosmetically acceptable salt thereof wherein: AA1 is Leu, Ile or Val; AA2 is Pro, Ala or Gly; AA3 is Val, Ile or Leu; AA4 is Thr...
|
|
WO/2024/033278A1 |
The invention relates to a novel process for manufacturing 4-[(11S,14S,17S)-14-(4-Aminobutyl)-11-(3-aminopropyl)-17-(1H
-indol-3-ylmethyl)-16-methyl-12,15,18-trioxo-2-thia-4,10,13,
16,19-pentazatricyclo[19.4.0.03,8]pentacosa-1(25),3(8),4...
|
|
WO/2024/032852A1 |
The invention relates to the natural product cycloacetamides A to F as novel metabolite from Mortierella alpina, to a process for production thereof, to the use thereof, and to the Mortierella alpina DSM 34346 strain. The object of the p...
|
|
WO/2024/031963A1 |
Disclosed are a chimeric compound for degrading cyclophilin A, a preparation method therefor, and use thereof. The structural formula of the chimeric compound is represented by formula I. The compound represented by formula I provided by...
|
|
WO/2024/031965A1 |
Disclosed are a PROTAC compound with cyclophilin A degradation activity, a preparation method therefor, and use thereof. The structural formula of the PROTAC compound is represented by formula (I). The compound represented by formula (I)...
|
|
WO/2024/029630A1 |
The present disclosure provides a cyclic peptide derivative, a method for producing the same, and a composition. The present disclosure pertains to a compound for neural cell activity regulation. More specifically, the compound of the pr...
|
|
WO/2024/025396A1 |
The present invention relates to an uristatin precursor drug and, more specifically, to an auristatin precursor drug bearing a self-immolative group, a preparation method therefor, a pharmaceutical composition comprising same, and a use ...
|
|
WO/2024/025890A1 |
The invention provides novel methods for preparing camptothecin derivatives and their synthetic precursors.
|
|
WO/2024/022483A1 |
The invention belongs to the technical field of pharmaceutical synthesis and relates to a bifunctional pharmaceutical intermediate and a preparation method and use thereof. The invention discloses a compound of formula (A) and a variety ...
|
|
WO/2024/023332A1 |
The invention relates to novel silicon-based fluoride acceptor groups (SiFA groups) of the following formulae (Ia, Ib, Ic) as well as to compounds suitable for use in radiopharmacy comprising such groups, wherein R1 and R2 are each a lin...
|
